721 related articles for article (PubMed ID: 27061322)
41. Role of Proteomics in the Development of Personalized Medicine.
Jain KK
Adv Protein Chem Struct Biol; 2016; 102():41-52. PubMed ID: 26827601
[TBL] [Abstract][Full Text] [Related]
42. Driving Precision Medicine through Proteomics and Metabolomics - 12th Central and Eastern European Proteomic Conference (CEEPC), Bucharest, Romania.
Gadher SJ; Antohe F; Kovarova H
Expert Rev Proteomics; 2019 Jul; 16(7):549-552. PubMed ID: 31204883
[TBL] [Abstract][Full Text] [Related]
43. Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders.
Singh S; Sarma DK; Verma V; Nagpal R; Kumar M
Biochem Biophys Res Commun; 2023 Nov; 682():1-20. PubMed ID: 37788525
[TBL] [Abstract][Full Text] [Related]
44. High resolution metabolomics technology reveals widespread pathway changes of alcoholic liver disease.
Zhang A; Yan G; Zhou X; Wang Y; Han Y; Guan Y; Sun H; Wang X
Mol Biosyst; 2016 Jan; 12(1):262-73. PubMed ID: 26593868
[TBL] [Abstract][Full Text] [Related]
45. Metabolomics through the lens of precision cardiovascular medicine.
Lam SM; Wang Y; Li B; Du J; Shui G
J Genet Genomics; 2017 Mar; 44(3):127-138. PubMed ID: 28325553
[TBL] [Abstract][Full Text] [Related]
46. Oncoproteomics: Trials and tribulations.
Zhou L; Li Q; Wang J; Huang C; Nice EC
Proteomics Clin Appl; 2016 Apr; 10(4):516-31. PubMed ID: 26518147
[TBL] [Abstract][Full Text] [Related]
47. Proteomics and Metabolomics in Kidney Disease, including Insights into Etiology, Treatment, and Prevention.
Dubin RF; Rhee EP
Clin J Am Soc Nephrol; 2020 Mar; 15(3):404-411. PubMed ID: 31636087
[TBL] [Abstract][Full Text] [Related]
48. Omics sciences and precision medicine in melanoma.
Medori MC; Donato K; Dhuli K; Maltese PE; Tanzi B; Tezzele S; Mareso C; Miertus J; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Beccari T; Ceccarini MR; Gisondi P; Bellinato F; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):29-36. PubMed ID: 37994746
[TBL] [Abstract][Full Text] [Related]
49. Proteomics-based technologies in the discovery of biomarkers for multiple sclerosis in the cerebrospinal fluid.
Lourenço AS; Baldeiras I; Grãos M; Duarte CB
Curr Mol Med; 2011 Jun; 11(4):326-49. PubMed ID: 21506919
[TBL] [Abstract][Full Text] [Related]
50. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases.
Quinones MP; Kaddurah-Daouk R
Neurobiol Dis; 2009 Aug; 35(2):165-76. PubMed ID: 19303440
[TBL] [Abstract][Full Text] [Related]
51. Novel strategies for clinical investigation and biomarker discovery: a guide to applied metabolomics.
Carneiro G; Radcenco AL; Evaristo J; Monnerat G
Horm Mol Biol Clin Investig; 2019 Jan; 38(3):. PubMed ID: 30653466
[TBL] [Abstract][Full Text] [Related]
52. Minireview: Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine.
Goodman SR; Pace BS; Hansen KC; D'alessandro A; Xia Y; Daescu O; Glatt SJ
Exp Biol Med (Maywood); 2016 Apr; 241(7):772-81. PubMed ID: 27022133
[TBL] [Abstract][Full Text] [Related]
53. Integrated Proteomics and Metabolomic Analyses of Plasma Injury Biomarkers in a Serious Brain Trauma Model in Rats.
Song T; Zhu Y; Zhang P; Zhao M; Zhao D; Ding S; Zhu S; Li J
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791599
[TBL] [Abstract][Full Text] [Related]
54. Metabolomics as a promising tool for improving understanding of multiple sclerosis: A review of recent advances.
Liu Z; Waters J; Rui B
Biomed J; 2022 Aug; 45(4):594-606. PubMed ID: 35042018
[TBL] [Abstract][Full Text] [Related]
55. UPLC-MS(E) application in disease biomarker discovery: the discoveries in proteomics to metabolomics.
Zhao YY; Lin RC
Chem Biol Interact; 2014 May; 215():7-16. PubMed ID: 24631021
[TBL] [Abstract][Full Text] [Related]
56. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine.
Honda K; Ono M; Shitashige M; Masuda M; Kamita M; Miura N; Yamada T
Jpn J Clin Oncol; 2013 Feb; 43(2):103-9. PubMed ID: 23248327
[TBL] [Abstract][Full Text] [Related]
57. The role of proteomics and metabolomics in severe infections.
Póvoa P; Bos LDJ; Coelho L
Curr Opin Crit Care; 2022 Oct; 28(5):534-539. PubMed ID: 35942690
[TBL] [Abstract][Full Text] [Related]
58. Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.
Latosinska A; Frantzi M; Vlahou A; Merseburger AS; Mischak H
Proteomics Clin Appl; 2018 Mar; 12(2):. PubMed ID: 28980455
[TBL] [Abstract][Full Text] [Related]
59. Intravital biobank and personalized cancer therapy: the correlation with omics.
Luo J; Guo XR; Tang XJ; Sun XY; Yang ZS; Zhang Y; Dai LJ; Warnock GL
Int J Cancer; 2014 Oct; 135(7):1511-6. PubMed ID: 24285244
[TBL] [Abstract][Full Text] [Related]
60. Metabolomics as a tool for drug discovery and personalised medicine. A review.
Mastrangelo A; Armitage EG; García A; Barbas C
Curr Top Med Chem; 2014; 14(23):2627-36. PubMed ID: 25515755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
